Skip to content

HIV self-testing increases uptake of HIV testing, but with poorer linkage to care

Domizia Salusest | www.domiziasalusest.com

The Buenos Aires patient: Argentinian woman controls HIV for at least 12 years after stopping treatment

Buenos Aires, Argentina. Andrea Leopardi/Unsplash

Products to prevent both pregnancy and HIV begin to emerge

Dr Alexandra Minnis presenting to HIVR4P 2021.

Nearly a million have started taking PrEP worldwide – only a third of UNAIDS’ 2020 target

Kate Segal presenting to HIVR4P 2021.

New ethical obligations for researchers in places where existing HIV prevention services are inadequate

Peter Godfrey-Faussett (top right) presenting at HIVR4P 2021.

Once-a-month PrEP pill easily passes its first big test

Professor Sharon Hillier at HIVR4P

A triumph for injectable PrEP, but a sobering result for oral PrEP

Professor Sinead Delany-Moretlwe presenting HPTN 084's study design

Antibody-based PrEP did not stop most types of HIV – but is still hailed as a ‘game changer’

Professor Larry Corey, principal researcher of the AMP studies, speaking at HIVR4P

European PrEP programmes face two big issues: how to get more people coming forward, and how to serve them if they do

Slide from the EACS Standard of Care meeting online workshop.